| Pulmonary Emphysema
Perforomist vs Stiolto Respimat
Side-by-side clinical, coverage, and cost comparison for pulmonary emphysema.Deep comparison between: Perforomist vs Stiolto Respimat with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsStiolto Respimat has a higher rate of injection site reactions vs Perforomist based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Stiolto Respimat but not Perforomist, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Perforomist
Stiolto Respimat
At A Glance
Nebulization
Twice daily
Long-acting beta2-agonist (LABA)
Oral inhalation
Once daily
LAMA/LABA
Indications
- Chronic Obstructive Airway Disease
- Bronchitis, Chronic
- Pulmonary Emphysema
- Chronic Obstructive Airway Disease
- Bronchitis, Chronic
- Pulmonary Emphysema
Dosing
Chronic Obstructive Airway Disease, Bronchitis, Chronic, Pulmonary Emphysema 20 mcg (one unit-dose vial) administered twice daily (morning and evening) by nebulization via standard jet nebulizer connected to an air compressor; total daily dose greater than 40 mcg is not recommended.
Chronic Obstructive Airway Disease, Bronchitis, Chronic, Pulmonary Emphysema Two inhalations once-daily at the same time of day via the STIOLTO RESPIMAT inhaler; do not use more than two inhalations every 24 hours.
Contraindications
- Use without an inhaled corticosteroid in patients with asthma
- Use of LABA without inhaled corticosteroid in patients with asthma
- Hypersensitivity to tiotropium, ipratropium, olodaterol, or any component of this product
Adverse Reactions
Most common (>=2%) Diarrhea, nausea, nasopharyngitis, dry mouth, vomiting, dizziness, insomnia
Serious Angina, hypertension or hypotension, tachycardia, arrhythmias, hypokalemia, hyperglycemia, metabolic acidosis
Postmarketing Anaphylactic reactions, urticaria, angioedema, rash, bronchospasm
Most common (>3%) nasopharyngitis, cough, back pain
Serious COPD exacerbation, pneumonia
Pharmacology
Long-acting beta2-adrenergic receptor agonist (LABA) that acts locally in the lung as a bronchodilator; stimulates adenyl cyclase to increase cyclic AMP levels, causing relaxation of bronchial smooth muscle and inhibition of mast cell mediator release.
Stiolto Respimat combines tiotropium, a long-acting muscarinic antagonist that inhibits M3-receptors at airway smooth muscle to produce bronchodilation, and olodaterol, a LABA that activates beta2-adrenoceptors to stimulate cAMP synthesis and relax airway smooth muscle cells.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Perforomist
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (10/12)
Stiolto Respimat
- Covered on 5 commercial plans
- PA (4/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Perforomist
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (5/8)
Stiolto Respimat
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (7/8)
Humana
Perforomist
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (3/3)
Stiolto Respimat
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Perforomist.
No savings programs available for Stiolto Respimat.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
PerforomistView full Perforomist profile
Stiolto RespimatView full Stiolto Respimat profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.